Adaptimmune Therapeutics Plc EBITDA margin
What is the EBITDA margin of Adaptimmune Therapeutics Plc?
The EBITDA margin of Adaptimmune Therapeutics Plc is -4,599.77%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to Adaptimmune Therapeutics Plc
What does Adaptimmune Therapeutics Plc do?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Companies with ebitda margin similar to Adaptimmune Therapeutics Plc
- Roboserver Systems has EBITDA margin of -4,695.63%
- First Trust New Opportunities MLP & Fund has EBITDA margin of -4,669.69%
- Black Rock Mining has EBITDA margin of -4,651.93%
- Alltemp has EBITDA margin of -4,650.43%
- China Oceanwide has EBITDA margin of -4,637.58%
- DiscovEx Resources has EBITDA margin of -4,636.53%
- Adaptimmune Therapeutics Plc has EBITDA margin of -4,599.77%
- Elixir has EBITDA margin of -4,580.94%
- Luduson G has EBITDA margin of -4,564.89%
- Consolidated Firstfund Capital has EBITDA margin of -4,562.43%
- Entera Bio Ltd has EBITDA margin of -4,559.35%
- Avira Resources has EBITDA margin of -4,527.45%
- Poseidon Nickel has EBITDA margin of -4,489.84%